Could E-Cigarettes Cause Bladder Cancer?

According to the results of a recently published study, carcinogenic biomarkers strongly linked to bladder cancer risk are found in the urine samples of electronic cigarette (e-cigarette) users.E-cigarettes contain nicotine, additives, and other chemical solvents that can create numerous toxic compounds when heated. Their popularity has increased dramatically in recent years, especially in the adolescent and young adult population. Between 2017 and 2018, usage increased nearly 80% among high sch...
Continue reading

Nadofaragene Firadenovec in Non–Muscle-Invasive Bladder Cancer: Colin Dinney, MD

​High-grade non–muscle-invasive bladder cancer that does not respond to intravesical Bacillus Calmette-Guerin (BCG) therapy carries a substantial risk of disease recurrence and progression, and effective salvage intravesical therapies are sorely needed for patients who are unable or unwilling to undergo cystectomy. According to results of a multicenter, open-label phase 3 trial presented in February at the American Society of Clinical Oncology (ASCO) 2020 Genitourinary Cancers Symposium, intrave...
Continue reading

Nadofaragene for High-Grade BCG-Unresponsive NMIBC

​Intravesical nadofaragene firadenovec is an effective and well-tolerated treatment for high-grade nonmuscle invasive bladder cancer (NMIBC) carcinoma in situ (CIS) that does not respond to intravesical Bacillus Calmette-Guerin (BCG), according to results of a multicenter, open-label phase 3 trial presented this past Friday at the 2020 Genitourinary Cancers Symposium.For patients with BCG-unresponsive NMIBC, there is a substantial risk of disease recurrence and progression. Cystectomy is often a...
Continue reading

Pembrolizumab Approval: Non-Muscle Invasive Bladder Cancer

The FDA has approved pembrolizumab (Keytruda®, Merck) for the treatment of patients with high-risk non-muscle invasive bladder cancer (NMIBC) carcinoma in situ, with or without papillary tumors. Pembrolizumab, a programmed cell death protein 1 (PD-1) inhibitor, is indicated for patients who are ineligible for or have elected not to receive radical cystectomy and who do not respond to bacillus Calmette-Guérin (BCG) therapy.The approval was based on Keynote 057 (NCT02625961), a multicenter, single...
Continue reading

Gemcitabine Plus Eribulin in Metastatic Urothelial Carcinoma

The phase 2 California Cancer Consortium trial has reported its final results: a combined regimen of gemcitabine (Gemzar®, Eli Lilly) plus eribulin (Halaven®, Eisai Inc.) shows efficacy in patients with metastatic urothelial carcinoma who are ineligible for cisplatin-based treatment. Many patients with urothelial carcinoma—the most common type of bladder cancer—that has metastasized are ineligible for chemotherapy treatments containing cisplatin. As such, alternatives are needed for th...
Continue reading

Copyright © 2020 i3 Health. All rights reserved.